MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 408146 | Name: SRX3207
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SRX3207 is a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression with IC50 of 39.9 nM. SRX3207 demonstrates efficacy in multiple tumor models and represents a novel combinatorial approach to activate antitumor immunity. SRX3207 potently inhibited Syk and PI3K signaling and augmented the anti-tumor immune response in lung carcinoma tumor model with no toxicity.

Chemical Structure

SRX3207
CAS#2254693-15-5

Theoretical Analysis

MedKoo Cat#: 408146

Name: SRX3207

CAS#: 2254693-15-5

Chemical Formula: C29H29N7O3S

Exact Mass: 555.2053

Molecular Weight: 555.66

Elemental Analysis: C, 62.69; H, 5.26; N, 17.65; O, 8.64; S, 5.77

Price and Availability

Size Price Availability Quantity
25mg USD 550.00 2 Weeks
50mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
200mg USD 2,650.00 2 Weeks
500mg USD 3,950.00 2 Weeks
1g USD 4,950.00 2 Weeks
2g USD 7,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SRX3207; SRX-3207; SRX 3207;
IUPAC/Chemical Name
3-[4-[[4-[4-(1-Azetidinylmethyl)-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]phenyl]-5-(4-morpholinyl)-7H-thieno[3,2-b]pyran-7-one
InChi Key
ZZVOPDBZUNUMPR-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H29N7O3S/c1-19-21(16-34-9-2-10-34)17-36(33-19)25-7-8-30-29(32-25)31-22-5-3-20(4-6-22)23-18-40-28-24(37)15-26(39-27(23)28)35-11-13-38-14-12-35/h3-8,15,17-18H,2,9-14,16H2,1H3,(H,30,31,32)
SMILES Code
O=C1C2=C(C(C3=CC=C(NC4=NC=CC(N5N=C(C)C(CN6CCC6)=C5)=N4)C=C3)=CS2)OC(N7CCOCC7)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Macrophages (MΦ) play a critical role in tumor growth, immunosuppression, and inhibition of adaptive immune responses in cancer. Hence, targeting signaling pathways in MΦs that promote tumor immunosuppression will provide therapeutic benefit. PI3Kγ has been recently established by our group and others as a novel immuno-oncology target.
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SRX3207 is a Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively.
In vitro activity:
This study developed in silico the dual Syk/PI3K inhibitor, SRX3207, for the combinatorial inhibition of Syk and PI3K in one small molecule. Reference: Mol Cancer Ther. 2020 Mar;19(3):755-764. https://pubmed.ncbi.nlm.nih.gov/31974273/
In vivo activity:
To be determined
Solvent mg/mL mM comments
Solubility
DMSO 5.0 9.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 555.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764. doi: 10.1158/1535-7163.MCT-19-0947. Epub 2020 Jan 23. PMID: 31974273; PMCID: PMC7450492.
In vitro protocol:
1. Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764. doi: 10.1158/1535-7163.MCT-19-0947. Epub 2020 Jan 23. PMID: 31974273; PMCID: PMC7450492.
In vivo protocol:
To be determined
Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764. doi: 10.1158/1535-7163.MCT-19-0947. Epub 2020 Jan 23. PMID: 31974273; PMCID: PMC7450492.